Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02487407
Recruitment Status : Completed
First Posted : July 1, 2015
Last Update Posted : November 28, 2017
Sponsor:
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

Tracking Information
First Submitted Date  ICMJE June 8, 2015
First Posted Date  ICMJE July 1, 2015
Last Update Posted Date November 28, 2017
Actual Study Start Date  ICMJE July 2015
Actual Primary Completion Date May 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 26, 2015)
Slow vital capacity SVC [ Time Frame: 9 months ]
Pulmonary assessment
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 26, 2015)
  • Hand grip strength and submaximal hand grip strength endurance [ Time Frame: 3 months ]
    Assessment
  • Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C) [ Time Frame: 3 months ]
    Scales
  • Quality of life [ Time Frame: 9 months ]
    Questionnaire
  • Revised ALS Functional Rating Scale ALSFRS-R [ Time Frame: 9 months ]
    Scale
  • Oxygen saturation [ Time Frame: 9 months ]
    Assessment
  • The concentrations of ODM-109, OR-1855 and OR-1896 [ Time Frame: 3 months ]
    Pharmacokinetics Blood samples.
  • Determination of subject's acetylation status [ Time Frame: 1 day (once at baseline) ]
    Pharmacogenomics Blood samples.
  • Sniff nasal pressure SNP [ Time Frame: 9 months ]
    SNP will be assessed in sitting position. SNP will be performed for 10 times. The highest value (cmH2O) measured will be the SNP variable.
  • Fatigue assessment [ Time Frame: 3 months ]
    Visual analogue Scale VAS
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis
Official Title  ICMJE Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension
Brief Summary

In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) after the start of study treatment. After completing the 3rd treatment period, the subjects will continue in the open-label follow-up part for 6 months. During the open-label follow-up, visits will be at 1, 3 and 6 months. An end-of-study visit will take place 14-25 days after the last study treatment administration for each subject. The study duration will be about 13-14 weeks for the double-blind cross-over part, and about 9-10 months for the entire study including the 6 months open-label follow-up.

The number of randomised study subjects is planned to be approximately 54 in cross-over comparison. The maximum number of subjects will not exceed 70.

Primary objective is to investigate the efficacy of oral ODM-109 on respiratory function in patients with amyotrophic lateral sclerosis (ALS).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Amyotrophic Lateral Sclerosis
Intervention  ICMJE
  • Drug: ODM-109
    ODM-109 1 mg capsule for oral administration.
    Other Name: Levosimendan
  • Drug: Placebo for ODM-109
    Placebo capsule for oral administration.
    Other Name: Placebo for Levosimendan
Study Arms  ICMJE
  • Experimental: ODM-109
    ODM-109 capsules for oral administration
    Interventions:
    • Drug: ODM-109
    • Drug: Placebo for ODM-109
  • Placebo Comparator: Placebo for ODM-109
    Placebo ODM-109 capsules for oral administration
    Interventions:
    • Drug: ODM-109
    • Drug: Placebo for ODM-109
Publications * Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 30, 2016)
66
Original Estimated Enrollment  ICMJE
 (submitted: June 26, 2015)
54
Actual Study Completion Date  ICMJE June 2017
Actual Primary Completion Date May 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness).
  • Age of at least 18 years.
  • Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available compatible with ALS according to an experienced neurophysiologist.
  • Ability to swallow the study treatment capsules.
  • An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at screening visit.
  • Normal oxygen saturation during daytime (measure of ≥ 95% when steady state has been reached with a reliable read) in sitting position measured by pulse oximetry.
  • Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 months.
  • Using riluzole. The dose must have been stable for at least 4 weeks prior to screening at a dose of 50 mg b.i.d.

Exclusion Criteria:

  • Subject in whom other causes of neuromuscular weakness have not been excluded.
  • Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease).
  • Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or predicted to be required within the randomised, double-blind cross-over part of the study.
  • Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia.
  • Any major surgery within 1 month before the screening visit or patients who are scheduled for any major surgery during the planned study period.
  • Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening.
  • Creatinine > 170 μmol/l at screening or on dialysis.
  • Blood haemoglobin < 10 g/dl at screening.
  • Clinically significant hepatic impairment at the discretion of the investigator.
  • Women of reproductive age without a negative pregnancy test and without a commitment to using an acceptable method of barrier or hormonal contraception (e.g. condoms, diaphragms, oral contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included.
  • Known hypersensitivity to levosimendan.
  • Administration of levosimendan within 30 days prior to screening visit.
  • Patients with history of botulinum toxin treatment for any reason.
  • Patients with known history of human immunodeficiency virus infection.
  • History of significant arrhythmias or other cardiac events
  • Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
  • Blood donation or loss of significant amount of blood within 60 days prior to screening.
  • Participation in a clinical trial with any experimental treatment within 30 days prior to the screening visit or previous participation in the present study.
  • Any other condition that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany,   Ireland,   Netherlands,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02487407
Other Study ID Numbers  ICMJE 3119001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Orion Corporation, Orion Pharma
Study Sponsor  ICMJE Orion Corporation, Orion Pharma
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Merja Mäkitalo, CSD Finland
PRS Account Orion Corporation, Orion Pharma
Verification Date August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP